Literature DB >> 23991846

Risks for hemorrhagic complications after placement of external ventricular drains with early chemical prophylaxis against venous thromboembolisms.

Omar Tanweer1, Akwasi Boah, Paul P Huang.   

Abstract

OBJECT: Patients undergoing placement of an external ventricular drain (EVD) are at increased risk for development of venous thromboembolisms (VTEs). Early chemical prophylaxis has been shown to decrease rates of embolism formation, but the risks for bleeding and the optimal time to initiate prophylaxis have not been clearly defined for this patient population. The authors evaluated the safety and risks for bleeding when chemical prophylaxis for VTEs was started within 24 hours of EVD placement.
METHODS: To compare rates of hemorrhage among patients who received prophylaxis within 24 hours and those who received it later than 24 hours after admission, the authors conducted an institutional review board-approved retrospective review. Patients were those who had had an EVD placed and postprocedural imaging conducted at Bellevue Hospital, New York, from January 2009 through April 2012. Data collected included demographics, diagnosis, coagulation panel results, time to VTE prophylaxis and imaging, and occurrence of VTEs. The EVD-associated hemorrhages were classified as Grade 0, no hemorrhage; Grade 1, petechial hyperdensity near the drain; Grade 2, hematoma of 1-15 ml; Grade 3, epidural or subdural hematoma greater than 15 ml; or Grade 4, intraventricular hemorrhage or hematoma requiring surgical intervention.
RESULTS: Among 99 patients, 111 EVDs had been placed. Low-dose unfractionated heparin had been given within 24 hours of admission (early prophylaxis) to 56 patients and later than 24 hours after admission (delayed prophylaxis) to 55 patients. There were no statistical differences across all grades (0-4) among those who received early prophylaxis (n = 45, 5, 5, 1, and 0, respectively) and those who received delayed prophylaxis (n = 46, 4, 1, 1, and 3, respectively) (p = 0.731). In the early prophylaxis group, 3 VTEs were discovered among 32 of 56 patients screened for clinically suspected VTEs. In the delayed prophylaxis group, 5 VTEs were discovered among 33 of 55 patients screened for clinically suspected VTEs (p = 0.71).
CONCLUSIONS: Hemorrhagic complications did not increase when chemical prophylaxis was started within 24 hours of admission. Also, the incidence of VTEs did not differ between patients in the early and delayed prophylaxis groups. Larger randomized controlled trials are probably needed to assess decreases in VTEs with earlier prophylaxis.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23991846     DOI: 10.3171/2013.7.JNS13313

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  6 in total

1.  Hemorrhage Rate After External Ventricular Drain Placement in Subarachnoid Hemorrhage: Time to Heparin Administration.

Authors:  Andrew P Gard; Brian D Sayles; J Will Robbins; William E Thorell; Daniel L Surdell
Journal:  Neurocrit Care       Date:  2017-12       Impact factor: 3.210

2.  Risk of Ventriculostomy-Associated Hemorrhage in Patients with Aneurysmal Subarachnoid Hemorrhage Treated with Anticoagulant Thromboprophylaxis.

Authors:  Joseph Zachariah; Kendall A Snyder; Christopher S Graffeo; Deependra R Khanal; Giuseppe Lanzino; Eelco F M Wijdicks; Alejandro A Rabinstein
Journal:  Neurocrit Care       Date:  2016-10       Impact factor: 3.210

3.  Hemorrhagic Complications Associated with Ventriculostomy in Patients Undergoing Endovascular Treatment for Intracranial Aneurysms: A Single-Center Experience.

Authors:  Jack M Leschke; Andrew Lozen; Mayank Kaushal; Akinwunmi Oni-Orisan; Mazen Noufal; Osama Zaidat; Glen A Pollock; Wade M Mueller
Journal:  Neurocrit Care       Date:  2017-08       Impact factor: 3.210

Review 4.  The Insertion and Management of External Ventricular Drains: An Evidence-Based Consensus Statement : A Statement for Healthcare Professionals from the Neurocritical Care Society.

Authors:  Herbert I Fried; Barnett R Nathan; A Shaun Rowe; Joseph M Zabramski; Norberto Andaluz; Adarsh Bhimraj; Mary McKenna Guanci; David B Seder; Jeffrey M Singh
Journal:  Neurocrit Care       Date:  2016-02       Impact factor: 3.210

5.  Safety of tirofiban and dual antiplatelet therapy in treating intracranial aneurysms.

Authors:  Edgar A Samaniego; Emilee Gibson; Daichi Nakagawa; Santiago Ortega-Gutierrez; Mario Zanaty; Jorge A Roa; Pascal Jabbour; David M Hasan
Journal:  Stroke Vasc Neurol       Date:  2019-02-03

6.  Venous thromboembolism chemical prophylaxis after endoscopic trans-sphenoidal pituitary surgery.

Authors:  Mueez Waqar; Annabel Chadwick; James Kersey; Daniel Horner; Tara Kearney; Konstantina Karabatsou; Kanna K Gnanalingham; Omar N Pathmanaban
Journal:  Pituitary       Date:  2021-11-29       Impact factor: 4.107

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.